Analysts Offer Insights on Healthcare Companies: Amag Pharmaceuticals (NASDAQ: AMAG), Agilent (NYSE: A) and Shire (NASDAQ: SHPG)

By Ryan Adsit

Analysts fell to the sidelines weighing in on Amag Pharmaceuticals (NASDAQ: AMAG), Agilent (NYSE: A) and Shire (NASDAQ: SHPG) with neutral ratings,indicating that the experts are neither bullish nor bearish on the stocks.

Amag Pharmaceuticals (NASDAQ: AMAG)

In a report released yesterday, Christopher Raymond from Piper Jaffray reiterated a Hold rating on Amag Pharmaceuticals (NASDAQ: AMAG), with a price target of $18. The company’s shares opened today at $16.65.

According to TipRanks.com, Raymond is a 5-star analyst with an average return of 26.8% and a 59.9% success rate. Raymond covers the Healthcare sector, focusing on stocks such as Alpine Immune Sciences Inc, Melinta Therapeutics Inc, and Alexion Pharmaceuticals.

Currently, the analyst consensus on Amag Pharmaceuticals is Hold and the average price target is $17.75, representing a 6.6% upside.

In a report issued on February 1, Cantor Fitzgerald also reiterated a Hold rating on the stock with a $17 price target.
Agilent (NYSE: A)

Cowen & Co. analyst Doug Schenkel reiterated a Hold rating on Agilent (NYSE: A) yesterday and set a price target of $80. The company’s shares opened today at $74.94, close to its 52-week high of $75.

According to TipRanks.com, Schenkel is a 4-star analyst with an average return of 7.1% and a 64.9% success rate. Schenkel covers the Healthcare sector, focusing on stocks such as Foundation Medicine, Becton Dickinson, and Oxford Immunotec.

Agilent has an analyst consensus of Strong Buy, with a price target consensus of $77.29.

Shire (NASDAQ: SHPG)

Piper Jaffray analyst David Amsellem reiterated a Hold rating on Shire (NASDAQ: SHPG) yesterday and set a price target of $150. The company’s shares opened today at $133.56, close to its 52-week low of $123.73.

According to TipRanks.com, Amsellem is ranked 0 out of 5 stars with an average return of -3.3% and a 42.5% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Supernus Pharmaceuticals, and Collegium Pharmaceutical.

Shire has an analyst consensus of Strong Buy, with a price target consensus of $198.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.